Study: Generic Semaglutide Production Costs Just $3 Monthly

Manufacturing Cost Analysis

According to a recent study published by Canadian Affairs News, researchers estimate the actual production cost for a month's supply of semaglutide at approximately $3 CAD. This figure represents the raw manufacturing expenses before distribution, marketing, and regulatory costs are added.

The analysis comes as nine generic manufacturers prepare applications for Health Canada review, with Ozempic and Wegovy patents having expired on January 4, 2026.

Current Pricing Landscape

Canadian patients currently face significant costs for semaglutide medications:

• Brand-name products: $400-$570 monthly out-of-pocket
• Projected generic pricing: $28-$140 annually according to some estimates
• Manufacturing cost floor: $3 monthly based on production analysis

The substantial gap between manufacturing costs and retail prices highlights the potential for dramatic price reductions once generic competition enters the Canadian market.

Generic Timeline and Market Entry

Health Canada is currently reviewing applications from multiple generic manufacturers, including established Canadian companies and international firms. Vimy Pharma, a domestic manufacturer, expects to file its application within weeks, joining eight other companies already under review.

Industry observers anticipate first generic approvals could arrive by summer 2026, though Health Canada has not provided specific timelines for individual applications. The generic semaglutide tracker continues monitoring these developments.

Economic Impact Projections

The $3 manufacturing cost figure provides context for potential generic pricing strategies in Canada. While final retail prices will include distribution, pharmacy margins, and other costs, the low production baseline suggests significant room for competitive pricing.

Current estimates from various sources project generic semaglutide could retail for:

• $100 monthly or less at Canadian pharmacies
• Potential bulk pricing for provincial drug plans
• Competitive positioning against Mounjaro and other brand alternatives

Insurance and Coverage Implications

The low manufacturing costs could influence provincial drug plan decisions regarding generic coverage. Several provinces are awaiting Health Canada approvals before determining coverage policies for generic versions.

Private insurers are also monitoring the generic landscape, with many employers expressing interest in covering lower-cost alternatives through their drug benefit programs. The insurance coverage checker provides current benefit information.

Regulatory Considerations

While manufacturing costs provide one data point, Health Canada's approval process focuses on safety, efficacy, and quality standards rather than pricing considerations. Generic manufacturers must demonstrate bioequivalence to approved brand-name products.

The regulatory review timeline remains Health Canada's standard 180-day process for generic applications, though complex injectable formulations may require additional review time.